

1st European CAR T Cell Meeting

14th-16th February 2019
Paris, France



Thursday, 14th February		Friday, 15th February		Saturday, 16th February			
TIME	AMPHITHEATRE	TIME	AMPHITHEATRE	TIME	AMPHITHEATRE	TTL ROOM	RVDA ROOM
8:30	Registration	8:30	08:30 - 10:00 SCIENTIFIC SESSION V Pre-clinical & clinical pipeline - Part I	8:30	08:30 - 09:45 SESSION XII General session - Part I	08:30 - 09:45 SESSION XIII Nurses session - Patient care - Part I	08:30 - 09:45 SESSION XIV Data managers session - Data collection & LTFU - Part I
8:45		8:45	Chairs: J. Delgado (Spain) & U. Koehl (Germany)	8:45	Chairs: R. Duarte (Spain) & A.A. van de Loosdrecht (The Netherlands)	Chairs: J. Murray (United Kingdom) & E. Aerts (Switzerland)	Chairs: J. Sierra (Spain) & P. Ljungman (Sweden)
9:00		9:00	• New targets and technologies for CAR-T cells M. Hudecek (Germany)	9:00	• CAR-T cells for non immunologists: A simple description of the technology M. Hudecek (Germany)	• What is driving CARs into the spotlight - The science simplified E. Vickers (United Kingdom)	• The Cell Therapy Form in the EBMT registry C. Ruiz de Eivira (United Kingdom)
9:15		9:15	• CAR-T-cell therapy for childhood solid tumours K. Straathof (United Kingdom)	9:15	• Current status of CAR-T cell development in Europe and elsewhere A. Urbano-Ispizua (Spain)	• A CAR-T for Everything - Overview of current studies and indications B. Davies (United Kingdom)	• The EMA initiative on registries E. McGrath (Spain)
9:30		9:30	• Prediclinical and clinical studies with CAR-T cells at the University of North Carolina G. Dotti (USA)	9:30	• Patient perspectives C. Chabannon (France)	• The supply chain for autologous CAR-T cell from a hospital perspective C. Chabannon (France)	• Specifics of LTFU for patients treated with gene therapy medicinal products A. van Biezen (The Netherlands)
9:45	Registration	9:45	• CARs, TRUCKS and beyond: the next generation of CAR T cells H. Abken (Germany)	9:45	Coffee break		
10:00		10:00	Q&A	10:00	10:15 - 12:00 SESSION XV General session - Part II	10:15 - 12:00 SESSION XVI Nurses session - Patient care - Part II	10:15 - 12:00 SESSION XVII Data managers session - Data collection & LTFU - Part II
10:15		10:15	10:00 - 10:45 KEY NOTE LECTURE SESSION VI • Next Generation CAR T Cells C. June (USA)	10:15	Chairs: N. Kröger (Germany) & J. Snowden (United Kingdom)	Chairs: E. Aerts (Switzerland) & R. Ellard (United Kingdom)	Chairs: M. Labopin (France) & J. Sierra (Spain)
10:30		10:30	Chairs: H. Einsele (Germany) & U. Koehl (Germany)	10:30	• Issues with centers selection and qualification T. Pagliuca (United Kingdom)	• Evaluation and Preparation of Pediatric Patients for CAR T-Cell Treatment D. Hutt (Israel)	• PASS Studies and CAR T: Regulatory requirements S.R. Tarvel (The Netherlands)
10:45		10:45	Coffee break	10:45	• Reimbursement C. Haag (Germany) & M. Dahan (France)	• Treatment and nursing assessment post CAR T cells in Ambulatory Care settings D. Comerford (United Kingdom)	• Example on registration TBA
11:00	Registration & Welcome lunch	11:00	Coffee break	11:00	• Patient perspectives N. Bolaños (Spain) & B. Verhoeven (The Netherlands)	• The EBMT Guidelines for practice / A framework for managing Patient Care, CRS and Neurotoxicity R. Ellard (United Kingdom) & O. Stewart (United Kingdom)	• From Promise to MACRO and minimized data sets P. Ljungman (Sweden)
11:15		11:15	Coffee break	11:15	• Round table discussion C. Haag (Germany) & M. Dahan (France)		
11:30		11:30	11:15 - 12:15 SESSION VII BEST ABSTRACTS & FLASH TALKS - Part II	11:30			
11:45		11:45	Chairs: A. Ruggeri (Italy) & M. Hudecek (Germany)	11:45			
12:00		12:00	12:15 - 13:00 SESSION VIII KEY NOTE LECTURE CAR T therapy: the next wave M. Sadelain (USA)	12:00			
12:15	12:30 - 12:45 OPENING CEREMONY • About EBMT/EAH and their activities N. Kröger (EBMT) & P. Sonneveld (EAH)	12:15	Chairs: A. Ruggeri (Italy) & C. Chomienne (France)	12:15		Lunch	
12:30		12:30	Lunch	12:30			
12:45		12:45	Lunch	12:45			
13:00		13:00	13:00 - 14:30 SATELLITE SYMPOSIUM BY KITE/GILEAD CAR T: TRANSFORMING OUTCOMES IN RELAPSE/REFRACTORY DLBCL	13:00	13:00 - 14:30 SESSION XIX Physicians session - Patient care - Part I	13:00 - 14:30 SESSION XXVIII General session - Part II - Repeat	13:00 - 14:30 SESSION XX Cell collection, cell processing facilities and hospital pharmacies personnel - Mastering the supply chain - Part I
13:15		13:15	Chairs: U. Jäger (Austria) & G. Salles (France)	13:15	Chairs: S. Izraeli (Israel) & C. de Haar (The Netherlands)	Chairs: A.A. van de Loosdrecht (The Netherlands) & J.O. Bay (France)	Chairs: M.J. Kersten (The Netherlands) & G. Basak (Poland)
13:30	14:15 - 15:15 SCIENTIFIC SESSION II When to use CAR-T in...	13:30	14:30 - 16:00 SESSION IX a: EMA & industry perspective on CAR-T in EU	13:30	• The Dutch experience for clinical implementation of CAR T cells in children and adults M. Minema (The Netherlands)	• CAR-T cells for non immunologists: A simple description of the technology M. Hudecek (Germany)	• Collection of autologous mononuclear cells H. Böning (Germany)
13:45		13:45	Chairs: M. Mohty (France) & H. Einsele (Germany)	13:45	• Management of CRS and neurotoxicities M. Topp (Germany)	• Current status of CAR-T cell development in Europe and elsewhere A. Urbano-Ispizua (Spain)	• Processing, QC and shipment of collected cells J. Larghero (France)
14:00		14:00	• CD19 - ALL/lymphoma C. Roddie (United Kingdom)	14:00	• A quality system for centers administering CAR T cells: The JACIE model E. McGrath (Spain)	• The supply chain for autologous CAR-T cell from a hospital perspective C. Chabannon (France)	• Point-of-care manufacturing J. Delgado (Spain)
14:15		14:15	• BCL2L1 - Myeloma A. Garfall (USA)	14:15			
14:30		14:30	• CD123 - AML E. Baudet (USA)	14:30			
14:45	Coffee break	14:45	15:00 - 16:30 SESSION XXII Physicians session - Patient care - Part II	14:45		Coffee break	
15:00		15:00	Chairs: S. Izraeli (Israel) & A. Mackensen (Germany)	15:00	15:00 - 16:30 SESSION XXI General session - Part II - Repeat	15:00 - 16:30 SESSION XXIII Cell collection, cell processing facilities and hospital pharmacies personnel - Mastering the supply chain - Part II	
15:15		15:15	• CAR-T cells - a regulatory view from the EMA Committee for Advanced Therapies M. Schüssler-Lenz (Germany)	15:15	Chairs: J. Murray (United Kingdom) & S. Montoto (United Kingdom)	Chairs: N. Worel (Austria) & W. Herr (Germany)	
15:30		15:30	• The EC's perspective on CAR-T in Europe D. Gancberg (Belgium)	15:30	• Issues with centers selection and qualification T. Pagliuca (United Kingdom)	• Role of the pharmacist in reception, storage and delivery of CAR T Cells. Transfer to the clinical ward and delivery of the gene therapy medicinal product C. de Haar (The Netherlands)	
15:45		15:45	• Reimbursement C. Haag (Germany)	15:45	• Reimbursement M. Dahan (France)	• Techniques for thawing cryopreserved CAR-T Cells B. Mfarrej (France)	
16:00	16:30 - 17:30 SESSION IV CAR-T in pediatrics	16:00	16:00 - 17:00 SESSION X Clinical implementation & management	16:00	• Patient perspectives N. Bolaños (France) & B. Verhoeven (The Netherlands)	• Out-of-Specification CAR-T Cell Products A. Bersenev (USA)	
16:15		16:15	Chairs: C. Chomienne & C. Rössig (Germany)	16:15	• The EBMT Registry: Fulfilling the needs of multiple stakeholders N. Kröger (Germany)		
16:30		16:30	16:30 - 17:30 SESSION XI Pre-clinical & clinical pipeline - Part II	16:30	• Evaluation of disease response A. Nagler (Israel)		
16:45		16:45	Chairs: F. Locatelli (Italy)	16:45	• Is this the end? The need for consolidation? Bridge to transplantation? CAR-T cells in treatment strategies S. Mielke (Sweden)		
17:00		17:00	• Würzburg experience M. Hudecek (Germany)	17:00	16:30 - 16:45 CLOSING REMARKS C. Chabannon (France) & H. Einsele (Germany)		
17:15	17:30 - 18:30 BEST ABSTRACTS & FLASH TALKS - Part I	17:15	• Lille experience J. Yacoub-Agha (France)	17:15			
17:30		17:30	• Milan experience F. Ciceri (Italy)	17:30			
17:45		17:45	• CART19-BE-01 trial J. Delgado (Spain)	17:45			
18:00		18:00	• RWE for CAR T evaluation D. Schulthess (The Netherlands)	18:00			
18:15		18:15	Chairs: M.J. Kersten (The Netherlands) & C. Thieblemont (France)	18:15			
18:30	Welcome reception & poster session	18:30	18:30 - 18:30 SESSION XI Pre-clinical & clinical pipeline - Part II	18:30			
18:45		18:45	Chairs: A.A. van de Loosdrecht (The Netherlands) & E. Ruggiero	18:45			
19:00		19:00	• TEGs J. Kuball (Germany)	19:00			
19:15		19:15	• CAR-T Treatment for B-cell ALL: Experiences from China P. Lu (China)	19:15			
19:30		19:30	• Cytokine release syndrome: Of men and (finally) of mice A. Bondanza (Italy)	19:30			
19:45	19:45	• Genome edited allo-CAR T cells W. Qasim (UK)	19:45				